Hsu, Ching-Sheng
Hsu, Shih-Jer
Liu, Wei-Liang
Chen, Ding-Shinn
Kao, Jia-Horng
Article History
Received: 16 April 2016
Accepted: 5 August 2016
First Online: 26 August 2016
Competing interests
: Ding-Shinn Chen has consulted for Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Roche and Merck Sharp & Dohme. Jia-Horng Kao has consulted for Bristol-Myers Squibb, Gilead Sciences and Novartis; on speaker’s bureau for Roche, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme and Novartis. All other authors declare no competing financial interests.